Drug Trial Radar · NCT07039669
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
594
Planned (sponsor's estimate)
Start
Jul 16, 2025
Primary completion
Sep 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.
Conditions
- Pulmonary Disease, Chronic Obstructive (COPD)
Interventions
611Drug
611 subcutaneous (SC) injection
PlaceboDrug
placebo Q2W, subcutaneous (SC) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized rate of moderate or severe COPD ExacerbationsTime frame: Baseline to Week 52
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Shenzhen People's Hospital
Shenzhen, Guangdong, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
ZheJiang Provincial People's Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.